No Data
Avidity Biosciences, Inc. (RNA): The Biotech Stock With Biggest Upside Potential
BofA Securities Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $51
Bank of America Securities Remains a Buy on Avidity Biosciences (RNA)
Barclays Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $63
Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (RNA), Celldex (CLDX) and Centessa Pharmaceuticals (CNTA)
H.C. Wainwright Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $72
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
